| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c099baf1bb1f52b8ab3809da83ca0927
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e856bd24c3eaa811c8657727571e9603
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e2613944636ab2fdf3f83ef2d4b304f0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_53995db5679fa93493ce58e29bdc7555 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-185
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-145
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-195
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-198
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-17 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-145
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-185
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-198 |
| filingDate |
2012-02-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5bf8d6d8162d40c39822db92665dbee5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8509138c43046f8eed8b5c6a563d05d0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b5355e6684e02c121e864c7ba92fcac4 |
| publicationDate |
2012-08-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2012113079-A1 |
| titleOfInvention |
Cystamine analogues for the treatment of parkinson's disease |
| abstract |
The present invention relates to the use of cystamine analogues for the treatment of Parkinson's disease. The present invention also relates to the use of composition comprising cystamine analogues and cysteine. The present invention relates to a method for modifying the progression of Parkinson's disease comprising administering a therapeutically effective amount of at least one cystamine analogue or a pharmaceutically acceptable salt of a cystamine analogue to a patient in need thereof. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10906904-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020198529-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11505550-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2016523364-A |
| priorityDate |
2011-02-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |